Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + SBRT + GnP in Advanced Pancreatic Cancer
NCT07336953Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2026
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 3 trial of serplulimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07336953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336953.